The question comes from a place of desperation, not curiosity.
A son watches his mother forget his name for the third time this week. A daughter sits in a neurologist’s waiting room with a folder of test reports, wondering if there is anything left to try. A family has been told that the medications are helping a little, that they need to manage expectations, that there is no cure.
Then they read about deep brain stimulation treatment for dementia online.
And they need an honest answer, not a website that gives them false hope and not one that dismisses the research entirely.
Why Dementia Is So Difficult to Treat: The Memory Circuit Problem
Dementia is not a single disease. It is an umbrella term for a group of conditions characterised by progressive cognitive decline, most commonly affecting memory, reasoning, language, and the ability to perform daily tasks.
Alzheimer’s disease accounts for 60 to 70% of all dementia cases globally. Dementia with Lewy bodies, vascular dementia, and frontotemporal dementia make up most of the remainder.
What links these conditions at a brain circuit level is damage to the networks responsible for memory encoding and retrieval. In Alzheimer’s disease specifically, the hippocampus, the fornix, the nucleus basalis of Meynert, and the wider Papez memory circuit are progressively damaged by the accumulation of amyloid plaques and tau tangles.
Current medications, cholinesterase inhibitors like donepezil and rivastigmine, and NMDA antagonists like memantine, work by boosting neurotransmitter levels to partially compensate for this damage. They offer modest symptomatic benefit. They do not slow the underlying disease process in any meaningful way.
Anti-amyloid antibodies like lecanemab and donanemab represent a newer frontier, showing slowed decline in early trials, but they carry significant safety concerns, are extremely costly, and are not yet widely available in India.
This gap, between what families need and what existing treatments offer, is exactly why researchers began investigating deep brain stimulation treatment for dementia.
“When families come to me asking about DBS for dementia, my first responsibility is to be honest. This is not Parkinson’s disease where DBS has decades of proven outcomes. For dementia, we are in a different scientific chapter. The research is real, the early results are encouraging, but this is still an emerging treatment. Families deserve to know exactly where the science stands.”
Dr. Jaspreet Singh Randhawa, MCh Neurosurgery (Gold Medalist), Medisyn Neuro Centre, Mohali
How Deep Brain Stimulation Treatment for Dementia Works
DBS for dementia operates on a fundamentally different principle than DBS for Parkinson’s disease or dystonia. In movement disorders, the goal is to suppress abnormal electrical activity in overactive circuits. In dementia, the goal is to stimulate and reactivate circuits that have gone quiet due to neurodegeneration.
The memory circuit targeted in dementia DBS research includes several key structures:
- The fornix: the primary outflow tract of the hippocampus; carries memory signals between the hippocampus and the rest of the Papez circuit; the most studied DBS target for Alzheimer’s disease
- Nucleus basalis of Meynert (NBM): the brain’s main source of acetylcholine, the neurotransmitter critical for attention, memory consolidation, and learning; severely damaged in Alzheimer’s disease
- Ventral striatum and ventral capsule (VS/VC): an emerging target showing early promise in slowing the overall rate of cognitive decline
The hypothesis is that electrical stimulation of these targets can increase hippocampal metabolic activity, modulate the Papez circuit, potentially reduce amyloid burden in surrounding tissue, and slow the progression of memory loss.
This is not reversing dementia. It is attempting to slow its advance, and the early evidence suggests this may be possible in the right patients at the right stage.
What the Clinical Trial Evidence Actually Shows
This is where most online articles either overstate the promise or dismiss the entire field. The honest picture is more nuanced.
Fornix DBS: The Most Studied Target
The first clinical trial of fornix DBS in Alzheimer’s disease was conducted in 2010. Since then, multiple studies have followed. A 2024 systematic review published in World Neurosurgery examined 14 human studies across three primary targets.
For fornix DBS specifically: in 5 of 6 distinct patient cohorts, cognitive decline was slowed based on standardised cognitive assessment scales including the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) and the Mini-Mental State Examination (MMSE).
This is meaningful. It does not mean patients improved dramatically. It means the rate at which they declined was slower than expected for their stage of disease, compared to patients not receiving the stimulation.
One important finding from these trials: younger patients, those under 65 years at diagnosis, showed greater benefit from fornix DBS than older patients. Patients in the mild to moderate stage of Alzheimer’s responded better than those with severe disease. Stage and age at intervention appear to be critical determinants of outcome.
Nucleus Basalis of Meynert DBS
NBM-DBS has been studied in smaller cohorts. In 2 of 3 published cohorts, a similar slowing of cognitive decline was observed. A notable finding from NBM stimulation is its more pronounced effect on neuropsychiatric symptoms of dementia, including agitation, mood disturbance, and behavioural changes, measured on the Neuropsychiatric Inventory (NPI) scale.
For Parkinson’s disease dementia (PDD) specifically, NBM stimulation in combination with STN-DBS for motor symptoms has shown improvement in global cognitive functions including memory, attention, alertness, and social communication in case reports.
The Key Limitation
The overall picture from the research, as summarised by a comprehensive PubMed systematic review of DBS trials in dementia, is that the population studied remains small, study designs vary significantly, and definitive conclusions about efficacy require larger, higher-quality randomised trials. Several are currently underway.
Deep brain stimulation treatment for dementia is not yet standard care anywhere in the world. It is at an advanced clinical trial stage, showing consistent enough early signals that major research centres globally are investing heavily in the next generation of trials.
| DBS Target | Primary Benefit | Evidence Stage | Best Candidate Stage |
|---|---|---|---|
| Fornix | Slowed cognitive decline; hippocampal metabolism boost | Phase 1 and 2 trials; 5 of 6 cohorts positive | Mild to moderate Alzheimer’s; under 65 |
| Nucleus Basalis of Meynert | Memory; attention; neuropsychiatric symptom improvement | Small cohort trials; 2 of 3 positive | Mild to moderate AD and Parkinson’s dementia |
| Ventral Striatum | Slowed overall decline on CDR scale | Phase 1 only; 3 patients studied | Investigational; very early stage |
“The phase 2b fornix trial was disappointing in its primary endpoint. But the secondary analysis told a different story for younger patients. Science rarely moves in a straight line. What that trial told us is that patient selection for dementia DBS is just as critical as it is for Parkinson’s, possibly more so.”
Dr. Jaspreet Singh Randhawa
DBS for Dementia vs Current Treatments: An Honest Comparison
Families evaluating all options deserve a side-by-side picture of where DBS sits relative to what is already available.
| Treatment | How It Works | Effect on Decline | Availability in India | Reversible |
|---|---|---|---|---|
| Cholinesterase inhibitors (donepezil, rivastigmine) | Increases acetylcholine in brain | Modest symptomatic benefit; does not slow disease | Widely available | Yes |
| Memantine | NMDA receptor modulation | Modest benefit in moderate to severe stage | Widely available | Yes |
| Anti-amyloid antibodies (lecanemab, donanemab) | Clears amyloid from brain | Slowed decline in mild AD; significant side effect risk | Very limited; not yet standard in India | Yes; stop infusions |
| DBS for dementia (fornix and NBM targets) | Stimulates memory circuits directly | Slowed decline in 5 of 6 fornix cohorts; promising NBM data | Clinical trial stage; not yet standard | Yes; device removable |
The honest conclusion: medications remain the first line and are widely accessible. DBS for dementia is not yet available as a standard treatment in India or globally. Patients who may be eligible for clinical trials abroad represent a small, specific group.
Who Could Potentially Benefit: What the Trials Tell Us About Patient Selection
Based on the available trial data, patients most likely to derive benefit from deep brain stimulation treatment for dementia in future well-designed studies share these characteristics:
- Diagnosis of mild to moderate Alzheimer’s disease confirmed by biomarkers (CSF or PET imaging), not just clinical assessment alone
- Age under 65 at time of diagnosis; younger patients showed more consistent benefit in fornix DBS trials
- Normal or near-normal brain MRI excluding other structural causes of cognitive decline
- Adequate response to or intolerance of standard medications; not in the very early stage where medications have not yet been tried adequately
- Cognitively capable of understanding and consenting to the procedure and its experimental nature
- Medically fit for surgical anaesthesia
Patients with severe dementia, extensive white matter disease, significant vascular damage, or other neurodegenerative conditions alongside Alzheimer’s are less likely to be appropriate candidates based on current evidence.
Is Deep Brain Stimulation for Dementia Available in India Right Now?
This is the question families most want answered directly.
As of 2025, deep brain stimulation treatment for dementia is not available as a standard clinical procedure in India. It is investigational globally. The trials that have produced results were conducted in research centres in North America, Europe, and Asia under highly controlled conditions.
What this means for Indian families today:
- Families whose loved ones have early-stage Alzheimer’s should optimise current medical management first; medications, lifestyle interventions, and cognitive stimulation programmes remain the foundation of care
- Patients who meet early trial criteria may be able to seek evaluation at research centres internationally; this requires biomarker-confirmed diagnosis, staging assessment, and specialist referral
- The landscape is evolving rapidly; DBS for dementia that reaches positive phase 3 trial outcomes could enter standard care guidelines within the next five to ten years
At Medisyn Neuro Centre, Mohali, Dr. Jaspreet Singh Randhawa performs the full range of established DBS procedures including surgery for Parkinson’s disease, essential tremor, dystonia, and drug-resistant epilepsy. For families dealing with dementia, his team provides honest assessment of where the patient stands, what established treatments remain available, and whether emerging options may become relevant over time.
“My job with dementia families is not to offer false comfort or false pessimism. It is to help them understand exactly where their loved one is in the disease, what works today, and how to stay informed about what is becoming available tomorrow. Dementia care is a long road, and families need a guide who tells them the truth at every turn.”
Dr. Jaspreet Singh Randhawa
What Families Can Do Right Now While Research Evolves
Waiting for science to catch up is not passive. There are meaningful actions families can take today that improve outcomes and quality of life for dementia patients, independent of what surgical options may become available.
- Confirm the diagnosis properly: Many patients carry a clinical dementia diagnosis without biomarker confirmation. A CSF analysis or amyloid PET scan can confirm whether the underlying pathology is Alzheimer’s disease, which matters for any future trial eligibility and for optimising current treatment choices
- Optimise current medications: Cholinesterase inhibitors work better when started early and dosed correctly. Many patients are not on optimal regimens. A movement disorder neurologist or cognitive neurologist review can identify gaps
- Structured cognitive stimulation: Evidence supports that structured mental engagement, social activity, and aerobic exercise slow cognitive decline meaningfully. These are not placebo interventions
- Vascular risk factor control: High blood pressure, diabetes, and high cholesterol all accelerate dementia progression. Aggressive management of these factors has a direct impact on the rate of decline
- Stay connected to specialist care: The dementia treatment landscape is moving faster than at any point in the past two decades. A functional neurosurgery team that follows the research will be able to inform families as options become clinically available
Research published in the PMC review on DBS as a potential treatment for dementia in Alzheimer’s and Parkinson’s disease dementia confirms that while DBS for these conditions is feasible and safe at the investigational level, it remains preliminary and requires confirmation from higher-quality trials. The Frontiers in Neuroscience systematic review and meta-analysis on DBS for Alzheimer’s disease provides the most comprehensive current picture of where the evidence stands across all three major targets.
10 Questions Families Ask About DBS for Dementia
1. Is DBS for dementia available in India right now?
Not as a standard clinical procedure. DBS for dementia is in the clinical trial stage globally. Established DBS for Parkinson’s disease, tremor, dystonia, and epilepsy is fully available in India including at Medisyn, Mohali.
2. Can DBS reverse dementia or restore lost memory?
No. Current evidence does not support memory restoration. The goal of DBS in dementia research is to slow the rate of cognitive decline, not reverse it. Memory already lost due to neurodegeneration cannot be recovered through stimulation.
3. My father has mild Alzheimer’s. Could he be a DBS trial candidate?
Possibly, if he meets specific criteria: biomarker-confirmed Alzheimer’s diagnosis, mild to moderate stage, normal structural MRI, and age typically under 65. Trial eligibility varies by study protocol. A specialist evaluation and biomarker testing are the starting points.
4. What is the fornix and why is it targeted in dementia DBS?
The fornix is a bundle of nerve fibres that connects the hippocampus to other parts of the memory circuit. It is one of the earliest structures damaged in Alzheimer’s disease. Stimulating it may increase hippocampal metabolic activity and slow the disruption of memory processing.
5. How Much Does Deep Brain Stimulation (DBS) Cost?
The cost of DBS varies depending on the country, hospital, surgeon, and type of device used. Expenses typically include pre-operative evaluations, surgery, the neurostimulator device, hospital stay, and follow-up programming sessions. Consulting a DBS specialist can provide a more accurate estimate based on your specific condition and treatment plan.
6. How is DBS for dementia different from DBS for Parkinson’s?
In Parkinson’s DBS, the goal is to suppress overactive motor circuits; the benefit is seen within weeks of activation. In dementia DBS, the goal is to reactivate underactive memory circuits; results are gradual and measured over months. The surgical procedure is similar but the brain target, programming approach, and expected outcome timeline differ significantly.
7. Could the surgery make dementia worse?
In published trials, no patient group showed accelerated cognitive decline attributable to DBS itself. However, the procedure carries the standard surgical risks of any brain surgery. In poorly selected patients, particularly those with severe dementia or significant cognitive impairment, surgical stress and anaesthesia can temporarily worsen confusion. Patient selection is therefore critical.
8. What happened in the phase 2b fornix DBS trial?
The phase 2b fornix trial did not meet its primary endpoint in the full study population. However, a pre-specified subgroup analysis showed that patients under 65 years at diagnosis had a meaningful slowing of decline. This led researchers to refine patient selection criteria for subsequent trials targeting younger, earlier-stage patients specifically.
9. What Is the Success Rate of Dementia DBS?
Dementia DBS is still experimental. While some studies show it may help slow cognitive decline in selected patients, there is currently no proven or standardized success rate through DBS. Results vary depending on the patient and stage of the disease.
10. How do I consult with Dr. Randhawa about a dementia case in our family?
The first step is a detailed specialist consultation where the diagnosis, staging, current medications, and imaging are all reviewed together. Dr. Randhawa at Medisyn Neuro Centre, Mohali provides functional neurosurgery evaluations and can advise on what current established options apply and how to monitor developments in emerging treatments like DBS for dementia. Book a consultation online to begin that conversation.
